Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 43 |
| Active Pipeline (Recruiting Now) | 22 (11) |
| Completed vs Stopped Early | 15 / 6 (13.9%) |
| Median Closed Actual Enrollment | 23 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Rochester | Rochester, NY | 18 |
| University of Rochester Medical Center | Rochester, NY | 15 |
| Saint Vincent Hospital Cancer Center Green Bay | Green Bay, WI | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05006482 | Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial | Phase III | RECRUITING |
| NCT05838716 | Vitamin D for Prostate Endocrine Therapy | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Rochester Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.